Novartis Announces $23 Billion US Investment 

• Novartis has announced a $23 billion investment over five years to expand its US-based manufacturing, research, and technology infrastructure.

• The expansion includes 10 facilities, nearly 5,000 new jobs, and the localisation of key medicine production in the US.

Novartis, a global pharmaceutical company, has announced a $23 billion investment over five years to expand its manufacturing and research presence across the United States. The company aims to ensure all key Novartis medicines for US patients are produced domestically.

The investment will fund the construction of 10 facilities, including seven new sites, creating nearly 1,000 jobs at Novartis and around 4,000 additional roles within the broader US economy. These facilities will support the production of both active pharmaceutical ingredients and biologics drug substances, as well as drug packaging and device assembly.

As part of the initiative, Novartis plans to establish a $1.1 billion biomedical research hub in San Diego, California. Four new manufacturing sites will also be built in states yet to be announced, alongside two radioligand therapy (RLT) facilities in Florida and Texas. Existing RLT facilities in Indiana, New Jersey, and California will be expanded.

The company noted that this expansion will allow it to bring the internal manufacturing of siRNA technology to the US for the first time and scale production across therapeutic areas including oncology, immunology, neuroscience, and cardiovascular diseases. These moves significantly increase Novartis’ capacity for contract manufacturing within the US.

“As a Swiss-based company with a significant presence in the US, these investments will enable us to fully bring our supply chain and key technology platforms into the US to support our strong US growth outlook,” said Vas Narasimhan, CEO of Novartis.

This expansion reinforces the US as a priority market for Novartis, with the total investment in US operations expected to reach nearly $50 billion over five years.